Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Affiliations

¹ Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France.
² Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁴ Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA.
⁵ Department of Internal Medicine III, University Hospital of Ulm, Germany.
⁶ Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁷ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
⁸ Department of Hematology, Jagiellonian University, Krakow, Poland.
⁹ Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA.
¹⁰ Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA.
¹¹ Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA.
¹² Gilead Sciences Inc., Foster City, CA, USA.
¹³ At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
¹⁴ Institute of Hematology and Oncology, University of Bologna, Italy.
¹⁵ Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA agopal@u.washington.edu.

Clinical Trial

Gilles Salles et al. Haematologica. 2017 Apr.

. 2017 Apr;102(4):e156-e159.

doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15.

¹ Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France.
² Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁴ Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA.
⁵ Department of Internal Medicine III, University Hospital of Ulm, Germany.
⁶ Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁷ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
⁸ Department of Hematology, Jagiellonian University, Krakow, Poland.
⁹ Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA.
¹⁰ Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA.
¹¹ Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA.
¹² Gilead Sciences Inc., Foster City, CA, USA.
¹³ At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
¹⁴ Institute of Hematology and Oncology, University of Bologna, Italy.
¹⁵ Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA agopal@u.washington.edu.

No abstract available

Figures

1. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin’s lymphoma. Cancer. 1997;80(12):2311–2320. - PubMed
1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276. - PMC - PubMed
1. Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev. 2012;26(6):279–288. - PMC - PubMed
1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23(22):5019–5026. - PubMed
1. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981–987. - PMC - PubMed